Please try another search
JCR Pharmaceuticals Co., Ltd., together with its subsidiaries, engages in the research, development, manufacture, import and export, and sale of pharmaceutical products, regenerative medicines, and drug substances in Japan. It offers various therapeutic products, including GROWJECT used for the treatment of growth hormone deficiency and short stature; IZCARGO to treat Mucopolysaccharidosis type II; Agalsidase Beta BS I.V. Infusion used for the treatment of Fabry disease; and TEMCELL HS Inj used to treat acute graft-versus-host disease. The company develops Epoetin Alfa BS and Darbepoetin Alfa BS Injections for the treatment of renal anemia. In addition, it sells, imports, and exports medical devices and laboratory instruments; and purchases and sells medical and research equipment. The company has a collaboration agreement with Angelini Pharma for the development of novel biologic therapies; and a. joint research agreement with Modalis Therapeutics Corporation to evaluate the drug delivery technology of the gene therapy to the central nervous system (CNS) assuming CNS diseases as a target. JCR Pharmaceuticals Co., Ltd. was incorporated in 1975 and is headquartered in Ashiya, Japan.
Name | Age | Since | Title |
---|---|---|---|
Toru Ashida | - | 2015 | Senior VP of Sales & Administration, Executive Director of Sales Division and Director |
Shin Ashida | 78 | 2005 | Chairman, CEO & President |
Kazumasa Oizumi | 76 | 2013 | Outside Audit & Supervisory Board Member |
Toshihiro Ishikiriyama | 71 | 2015 | Independent Outside Director |
Yuko Hayashi | 58 | - | Independent Outside Director |
Kenjiro Miyatake | 85 | 2013 | Outside Audit & Supervisory Board Member |
Takeshi Komura | 84 | 2017 | Outside Audit & Supervisory Board Member |
Philippe Fauchet | 66 | - | Independent Outside Director |
Takashi Suetsuna | 74 | - | Independent Outside Director |
Kazuhiko Yamada | 76 | 2006 | Outside Audit & Supervisory Board Member |
Shuichi Tani | 84 | 2017 | Outside Audit & Supervisory Board Member |
Yutaka Atomi | 79 | 2022 | Independent Outside Director |
Marc Dunoyer | 71 | 2023 | Independent Outside Director |
Toshihide Yoda | 60 | - | Independent Outside Director |
Hiroyuki Sonoda | 45 | 2018 | VP of Research & Corporate Strategy, Executive Director of Research Division and Director |
Mathias Schmidt | 55 | 2020 | VP of Clinical Development, Business Development & IR Fields and Senior Executive Director |
Yoshio Hiyama | 64 | 2021 | Sr. Exec. Director, Director of Regulatory Affairs Dept. & Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review